» Articles » PMID: 35334953

Efficacy of FODMAP Elimination and Subsequent Blinded Placebo-Controlled Provocations in a Randomised Controlled Study in Patients with Ulcerative Colitis in Remission and Symptoms of Irritable Bowel Syndrome: A Feasibility Study

Abstract

Background: Patients with inflammatory bowel disease (IBD) and symptoms of irritable bowel syndrome (IBS) may be intolerant to fermentable carbohydrates (FODMAPs). The aim of this study was to test the feasibility of eliminating and subsequently reintroducing FODMAPs in patients with IBS symptoms as part of the IBD manifestation and to compare the severity of IBS symptoms and pain, bloating and quality of life (QoL). Methods: An eight-week randomised open-label FODMAP elimination with double-blinded, crossover provocations of FODMAP and placebo. Diet patients were on a low-FODMAP diet for eight weeks with blinded two-week provocations after two and six weeks. Questionnaires, blood and stool samples were collected. Results: Patient enrolment was challenging. Nineteen participants were included in the study. Eliminating low FODMAP for two weeks resulted in significant decreases in pain and bloating scores (p < 0.003), whereas there were no statistical differences in pain scores between diet patients and controls. Pain and bloating scores increased, returning to baseline levels after two weeks of double-blinded provocations with placebo, (p > 0.05). Conclusions: The results document the possibility of performing a randomised controlled study following the gold standard for testing food intolerance with blinding of the Low FODMAP diet. Recruitment of participants was challenging.

Citing Articles

Dietary content and eating behavior in ulcerative colitis: a narrative review and future perspective.

Qin L, Lv W Nutr J. 2025; 24(1):12.

PMID: 39849464 PMC: 11755847. DOI: 10.1186/s12937-025-01075-y.


Effectiveness of a novel diet in attenuation of clinical activity of disease in patients with ulcerative colitis: a randomized, clinical trial.

Narimani B, Sadeghi A, Ebrahimi Daryani N, Shahrokh S, Nilghaz M, Ghods M Sci Rep. 2024; 14(1):13791.

PMID: 38877032 PMC: 11178895. DOI: 10.1038/s41598-024-64512-8.


Adverse Food Reactions in Inflammatory Bowel Disease: State of the Art and Future Perspectives.

Capobianco I, Di Vincenzo F, Puca P, Becherucci G, Mentella M, Petito V Nutrients. 2024; 16(3).

PMID: 38337636 PMC: 10857040. DOI: 10.3390/nu16030351.


Dietary Intervention Improves Gastrointestinal Symptoms after Treatment of Cancer in the Pelvic Organs.

Borre M, Fassov J, Poulsen J, Christensen P, Laurberg S, Drewes A J Clin Med. 2023; 12(14).

PMID: 37510881 PMC: 10380860. DOI: 10.3390/jcm12144766.


A Systematic Review of the Role of Diet in Ulcerative Colitis.

Abbas N, Shakil M, Akhtar Rana Z, Basharat Ali S, Ayub Awan A, Gul S Cureus. 2023; 15(5):e39350.

PMID: 37351247 PMC: 10284595. DOI: 10.7759/cureus.39350.


References
1.
Spiegel B, Camilleri M, Bolus R, Andresen V, Chey W, Fehnel S . Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report. Gastroenterology. 2009; 137(6):1944-53.e1-3. PMC: 2793276. DOI: 10.1053/j.gastro.2009.08.047. View

2.
Palsson O, Whitehead W, van Tilburg M, Chang L, Chey W, Crowell M . Rome IV Diagnostic Questionnaires and Tables for Investigators and Clinicians. Gastroenterology. 2016; . DOI: 10.1053/j.gastro.2016.02.014. View

3.
Halpin S, Ford A . Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2012; 107(10):1474-82. DOI: 10.1038/ajg.2012.260. View

4.
Ware Jr J, Sherbourne C . The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30(6):473-83. View

5.
Svedlund J, Sjodin I, DOTEVALL G . GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988; 33(2):129-34. DOI: 10.1007/BF01535722. View